This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnership About Centessa Pharmaceuticals Stock (NASDAQ:CNTA) Get CNTA alerts:Sign Up Key Stats Today's Range$40.50▼$40.5050-Day Range$39.62▼$40.7152-Week Range$12.74▼$40.56VolumeN/AAverage Volume2.15 million shsMarket Capitalization$6.27 billionP/E RatioN/ADividend YieldN/APrice Target$42.00Consensus RatingHold Company Overview Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain. Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders. Each affiliated research unit is advancing one or more drug candidates through discovery, preclinical studies and clinical trials. By maintaining strategic agility within its autonomous project teams, Centessa seeks to optimize development timelines and increase the probability of regulatory success. The company was formed in 2021 through an investment consortium and completed its initial public offering via a business combination with Narwhal Acquisition Corp. in early 2022. Headquartered in Cambridge, U.K., Centessa maintains a significant presence in the United States, with research and development sites located in key biotech hubs. This transatlantic footprint enables collaboration with leading academic institutions and access to diverse clinical trial networks. Under the leadership of Chief Executive Officer Knut Brundin, Centessa Pharmaceuticals draws on decades of industry experience to guide its strategic vision. The management team is complemented by veteran drug developers, regulatory experts and academic advisors, all committed to advancing novel therapies from laboratory research to patient care. AI Generated. May Contain Errors. Read More Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTA Stock News HeadlinesAcquisition of Centessa by Lilly Approved by the High Court of Justice of England and WalesJune 22, 2026 | globenewswire.comActinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline DevelopmentJune 1, 2026 | prnewswire.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 21 at 1:00 AM | Profits Run (Ad)Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?May 12, 2026 | prnewswire.comCentessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTAMay 11, 2026 | businesswire.comIs It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?May 4, 2026 | finance.yahoo.comCentessa Pharmaceuticals plc (CNTA)May 1, 2026 | finance.yahoo.comWells Fargo downgrades Centessa Pharmaceuticals plc - Depositary Receipt (CNTA)April 21, 2026 | msn.comSee More Headlines CNTA Stock Analysis - Frequently Asked Questions How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) released its quarterly earnings results on Tuesday, March, 31st. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.10. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $314 million in an initial public offering on Friday, May 28th 2021. The company issued 16,500,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. What other stocks do shareholders of Centessa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Palantir Technologies (PLTR), CrowdStrike (CRWD), Intuitive Surgical (ISRG), Pfizer (PFE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ASML (ASML). Company Calendar Today11/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CNTA CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees200Year Founded2021Price Target and Rating Average Price Target for Centessa Pharmaceuticals$42.00 High Price Target$62.00 Low Price Target$30.00 Potential Upside/Downside+3.7%Consensus RatingHold Rating Score (0-4)2.21 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$197.53 million Net MarginsN/A Pretax Margin-1,304.75% Return on Equity-60.37% Return on Assets-44.17% Debt Debt-to-Equity Ratio0.23 Current Ratio9.53 Quick Ratio9.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.92 per share Price / Book10.33Miscellaneous Outstanding Shares154,731,000Free Float148,403,000Market Cap$6.27 billion OptionableOptionable Beta1.11 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CNTA) was last updated on 6/25/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.